N-Benzyl-N-(tetrahydro-2H-pyran-4-yl)pyrrolidin-3-amines as selective dual serotonin/noradrenaline reuptake inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 7, 2007, Pages 2022-2025

  Fish, Paul V ^a   Fray, M Jonathan ^a   Stobie, Alan ^a   Wakenhut, Florian ^a   Whitlock, Gavin A ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

hERG; Metabolic stability; Noradrenaline reuptake; Serotonin reuptake; SNRI

Indexed keywords

AMINE; CYTOCHROME P450 2D6; DULOXETINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; VENLAFAXINE;

ARTICLE; DRUG ACTIVITY; DRUG METABOLISM; DRUG SELECTIVITY; DRUG STABILITY; ENZYME INHIBITION; IN VITRO STUDY; STEREOCHEMISTRY;

AMINES; CHEMISTRY, PHARMACEUTICAL; CYTOCHROME P-450 CYP2D6; DRUG DESIGN; ETHER-A-GO-GO POTASSIUM CHANNELS; HEPATOCYTES; HUMANS; INHIBITORY CONCENTRATION 50; LIGANDS; MICROSOMES; MODELS, CHEMICAL; MOLECULAR CONFORMATION; NOREPINEPHRINE; PYRROLIDINES; SEROTONIN UPTAKE INHIBITORS;

EID: 33847732615     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.01.020     Document Type: Article

References (20)

1. Joffe R.T., Marshall A.M., and Lee D.K. J. Clin. Psychiatry 59 (1998) 515
2. Hellerstein D.J., Batchelder S.T., Little S.A.S., Fedak M.J., Kreditor D., and Rosenthal J. J. Clin. Psychiatry 60 (1999) 845
3. Bauer M., Moeller H.-J., and Schneider E. Expert Opin. Pharmacother. 7 (2006) 421
4. Rowbotham M.C., Goli V., Kunz N.R., and Lei D. Pain 110 (2004) 697
5. Wernicke J.F., Pritchett Y.L., D'Souza D.N., Waninger A., Tran P., Iyengar S., and Raskin J. Neurology 67 (2006) 1411
6. Moore K. Int. J. Gynecol. Obstet. 86 S1 (2004) S53
7. Thor K.B. Int. J. Gynecol. Obstet. 86 S1 (2004) S38
8. Millard R.J., Moore K., Rencken R., Yalcin I., and Bump R.C. BJU Int. 93 (2004) 311
9. Fray M.J., Bish G., Brown A.D., Fish P.V., Stobie A., Wakenhut F., and Whitlock G.A. Bioorg. Med. Chem. Lett. 16 (2006) 4345
10. Fray M.J., Bish G., Fish P.V., Stobie A., Wakenhut F., and Whitlock G.A. Bioorg. Med. Chem. Lett. 16 (2006) 4349
11. After we completed this series, researchers at Eli Lilly independently published their own work in this area, Beadle, C. D.; Cases-Thomas, M. J.; Clark, B. P.; Gallagher, P. T.; Masters, J. J.; Timms, G. H.; Walter, M. W.; Whatton, M. A.; Wood, V. A.; Gilmore, J. WO2005000811.
12. 50 values, that is, concentration required to inhibit the specific uptake of radiolabelled substrate into the cells by 50% relative to maximum (vehicle only) over a 10-point dose-response range. A minimum of three experiments were made
13. Skinner M.H., Kuan H.-Y., Pan A., Sathirakul K., Knadler M.P., Gonzales C.R., Yeo K.P., Reddy S., Lim M., Ayan-Oshodi M., and Wise S.D. Clin. Pharm. Ther. 73 (2003) 170
14. Ereshefsky L., Riesenman C., and Lam Y.W. Clin. Pharmacokinet. 29 S1 (1995) 10
15. This is in contrast to the piperazine series described in Ref. 6, in which a 2-substituent delivers potent dual 5-HT and NA reuptake inhibition.
16. The human hepatocyte assay was able to accurately determine half-lives of up to 240 min, whereas the maximum measurable half-life in human liver microsomes was 120 min.
17. Fermini B., and Fossa A.A. Nat. Rev. Drug Disc. 2 (2003) 439
18. Keating M.T., and Sanguinetti M.C. Cell 104 (2001) 569
19. Finlayson K., Turnbull L., January C.T., Sharkey J., and Kelly J.S. Eur. J. Pharmacol. 430 (2001) 147
20. Jamieson C., Moir E.M., Rankovic Z., and Wishart G. J. Med. Chem. 49 (2006) 5029